Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Bone Metastases
Top Cited Papers
- 1 November 2002
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 42 (11), 1228-1236
- https://doi.org/10.1177/009127002762491316
Abstract
The pharmacokinetics, pharmacodynamics, and safety of zoledronic acid (Zometa®), a new‐generation bisphosphonate, were evaluated in 36 patients with cancer and bone metastases. Zoledronic acid (by sp...Keywords
This publication has 14 references indexed in Scilit:
- Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer, 2001
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001
- A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone diseaseCancer, 2001
- Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone.Calcified Tissue International, 1997
- Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short‐Term Rat ModelsBasic & Clinical Pharmacology & Toxicology, 1997
- Pharmacokinetics of Pamidronate Disodium in Patients with Cancer with Normal or Impaired Renal FunctionThe Journal of Clinical Pharmacology, 1997
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994
- Renal and Nonrenal Clearance of Clodronate in Patients with Malignancy and Renal ImpairmentClinical Drug Investigation, 1994
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976